Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 3;16(1):e51613.
doi: 10.7759/cureus.51613. eCollection 2024 Jan.

Advancing Anemia Management in Chronic Kidney Disease: Assessing the Superiority of Darbepoetin Alfa Over Erythropoietin Alpha

Dinesh Khullar  1 , Snehal S Muchhala  2 , Abhishek T  2
Affiliations
Review

Advancing Anemia Management in Chronic Kidney Disease: Assessing the Superiority of Darbepoetin Alfa Over Erythropoietin Alpha

Dinesh Khullar et al. Cureus. .

Abstract

Anemia is a prevalent and debilitating complication in patients with chronic kidney disease (CKD). It presents multifaceted challenges that impact patients' quality of life and overall well-being. The advent of darbepoetin alfa (DPO) as a therapeutic alternative to recombinant human erythropoietin alpha (EPO) has revolutionized the management of CKD-associated anemia. This review article presents a comprehensive comparative analysis highlighting the advantages of DPO over EPO in the effective management of anemia, in both predialysis and dialysis-dependent (DD) CKD patients. DPO's distinct pharmacokinetic advantages play a pivotal role in its efficacy and safety. With a significantly longer half-life and several-fold increased biological activity compared to EPO, DPO enables extended dosing intervals. Through an in-depth examination of diverse clinical trials, it becomes evident that DPO consistently demonstrates remarkable efficacy and safety in improving and maintaining hemoglobin (Hb) levels. Furthermore, its simplified dosage regimen, coupled with the convenience of less frequent administration, not only improves patient adherence but also translates to reduced healthcare costs and resource utilization. In conclusion, this review provides compelling evidence of the advantages of DPO over conventional recombinant human EPO for managing anemia in CKD patients, both in the predialysis and dialysis-dependent CKD patients. DPO's pharmacokinetic advantages, patient-centered advantages, enhanced compliance, and cost-effectiveness converge to establish DPO as a transformative therapeutic option. In both predialysis and dialysis settings, DPO's superior efficacy and patient-centric attributes collectively redefine the landscape of anemia management in CKD.

Keywords: anaemia management; chronic kidney disease (ckd); cost-effectiveness; darbepoetin alfa; erythropoietin alfa.

PubMed Disclaimer

Conflict of interest statement

Dr. Snehal Muchhala and Dr. Abhishek T are currently employees of Dr. Reddy’s Laboratories, which is one of the pharmaceutical companies marketing darbepoetin.

Figures

Figure 1
Figure 1. Features of darbepoetin alfa highlighting the superiority over erythropoietin alpha in anemia treatment for CKD patients
Image credits: Abhishek T
See this image and copyright information in PMC

References

    1. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. Hsu CY, McCulloch CE, Curhan GC. J Am Soc Nephrol. 2002;13:504–510. - PubMed
    1. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Portolés J, Martín L, Broseta JJ, Cases A. Front Med (Lausanne) 2021;8:642296. - PMC - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline... Kidney Int Suppl. 2012;2:279–335.
    1. Prevalence of anemia in chronic kidney disease in the United States. Stauffer ME, Fan T. PLoS One. 2014;9:0. - PMC - PubMed
    1. Prevalence of iron deficiency anemia among chronic kidney disease patients in Kaveri Delta region, Tamilnadu, India. Muniyandi D, Shanmugam N, Ramanathan K, Vijayaraghavan B, Padmanabhan G. https://pesquisa.bvsalud.org/portal/resource/pt/sea-183190 Br J Med Med Res. 2016;15:1–6.

LinkOut - more resources